AKT1 and malignant colon neoplasm: Oncogenic KRAS increased the levels of nuclear β-catenin and formation of nuclear β-catenin/Transcription factor 4 (TCF4) complex in colon cancer through inhibition of Glycogen synthase kinase-3β (GSK-3β), and these effects were blocked by the inhibitor of the phosphatidylinositide 3-kinases (PI3K)/AKT signaling pathway [6].